147 related articles for article (PubMed ID: 36380619)
1. Effect of Bilastine on Chronic Urticaria: A Systematic Review and Meta-Analysis.
Xue X; Wang Q; Yang X; Tu H; Deng Z; Kong D; Liu W; Fan Z; Li N
Int Arch Allergy Immunol; 2023; 184(2):176-185. PubMed ID: 36380619
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Bilastine on Symptoms of Allergic Rhinitis and Chronic Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Abdelshafy AM; Abdallah SY; Hassan AF; Mohamed HA; Kamal NM; Ali ST; Abdelhaleem IA
Am J Rhinol Allergy; 2022 Sep; 36(5):684-694. PubMed ID: 35593100
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II/III study.
Hide M; Yagami A; Togawa M; Saito A; Furue M
Allergol Int; 2017 Apr; 66(2):317-325. PubMed ID: 27599913
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases: an exploratory study.
Serra E; Campo C; Novák Z; Majorek-Olechowska B; Pulka G; García-Bea A; Labeaga L
J Dermatolog Treat; 2020 May; 31(3):270-278. PubMed ID: 30835579
[No Abstract] [Full Text] [Related]
5. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study.
Zuberbier T; Oanta A; Bogacka E; Medina I; Wesel F; Uhl P; Antépara I; Jáuregui I; Valiente R;
Allergy; 2010 Apr; 65(4):516-28. PubMed ID: 19860762
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness, safety, and tolerability of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic spontaneous urticaria: A double-blind, parallel group, randomized controlled trial.
Podder I; Das A; Ghosh S; Biswas D; Sengupta S; Chowdhury SN
Dermatol Ther; 2020 Nov; 33(6):e13946. PubMed ID: 32618048
[TBL] [Abstract][Full Text] [Related]
7. One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases.
Yagami A; Furue M; Togawa M; Saito A; Hide M
J Dermatol; 2017 Apr; 44(4):375-385. PubMed ID: 27862227
[TBL] [Abstract][Full Text] [Related]
8. Comparative Efficacy and Acceptability of Licensed Dose Second-Generation Antihistamines in Chronic Spontaneous Urticaria: A Network Meta-Analysis.
Phinyo P; Koompawichit P; Nochaiwong S; Tovanabutra N; Chiewchanvit S; Chuamanochan M
J Allergy Clin Immunol Pract; 2021 Feb; 9(2):956-970.e57. PubMed ID: 32916325
[TBL] [Abstract][Full Text] [Related]
9. Bilastine: in allergic rhinitis and urticaria.
Carter NJ
Drugs; 2012 Jun; 72(9):1257-69. PubMed ID: 22686617
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of Xiaofeng powder in the treatment of chronic urticaria: A systematic review and meta-analysis.
Bi C; Jia Y; Wei F
Medicine (Baltimore); 2024 Mar; 103(12):e37305. PubMed ID: 38518009
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of switching to bilastine, a histamine H1 receptor antagonist, in patients with chronic spontaneous urticaria (H1-SWITCH): study protocol for a randomized controlled trial.
Fukunaga A; Oda Y; Washio K; Omori T; Kakei Y; Hide M; Nishigori C
Trials; 2020 Jan; 21(1):23. PubMed ID: 31906999
[TBL] [Abstract][Full Text] [Related]
12. Bilastine: a lifetime companion for the treatment of allergies.
Church MK; Tiongco-Recto M; Ridolo E; Novák Z
Curr Med Res Opin; 2020 Mar; 36(3):445-454. PubMed ID: 31612732
[No Abstract] [Full Text] [Related]
13. Real-Life Experience of Efficacy and Safety of Bilastine in the Refractory Cases of Chronic Spontaneous Urticaria and its Effect on the Quality of Life of Patients.
De A; Godse K; Dhoot D; Sarda A
Indian J Dermatol; 2021; 66(2):159-164. PubMed ID: 34188271
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines.
Agache I; Rocha C; Pereira A; Song Y; Alonso-Coello P; Solà I; Beltran J; Posso M; Akdis CA; Akdis M; Brockow K; Chivato T; Del Giacco S; Eiwegger T; Eyerich K; Giménez-Arnau A; Gutermuth J; Guttman-Yassky E; Maurer M; Ogg G; Ong P; O'Mahony L; Schwarze J; Werfel T; Canelo-Aybar C; Palomares O; Jutel M
Allergy; 2021 Jan; 76(1):59-70. PubMed ID: 32767573
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Bilastine in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis.
Singh Randhawa A; Mohd Noor N; Md Daud MK; Abdullah B
Front Pharmacol; 2021; 12():731201. PubMed ID: 35082662
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and safety of bilastine in children aged 6 to 11 years with allergic rhinoconjunctivitis or chronic urticaria.
Rodríguez M; Vozmediano V; García-Bea A; Novák Z; Yáñez A; Campo C; Labeaga L
Eur J Pediatr; 2020 May; 179(5):801-805. PubMed ID: 31919579
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Omalizumab for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Jia HX; He YL
Am J Ther; 2020; 27(5):e455-e467. PubMed ID: 32427616
[TBL] [Abstract][Full Text] [Related]
18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
19. Open-label safety assessment of bilastine in elderly patients with allergic rhinoconjunctivitis and/or urticaria.
Sologuren A; Viñas R; Cordón E; Riesgo SE; Del Mar Forés M; Senán MR; Fernández S; Labeaga L; Ruiz-Miján M
Allergy Asthma Proc; 2018 Jul; 39(4):299-304. PubMed ID: 29559031
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients.
Bachert C; Kuna P; Sanquer F; Ivan P; Dimitrov V; Gorina MM; van de Heyning P; Loureiro A;
Allergy; 2009 Jan; 64(1):158-65. PubMed ID: 19132976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
